[1]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89-93.[doi:10.3969/j.issn.1006-1959.2020.02.024]
　ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Medical Information,2020,33(02):89-93.[doi:10.3969/j.issn.1006-1959.2020.02.024]
点击复制

自身免疫性肝炎合并自身免疫性疾病的特征研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年02期
页码:
89-93
栏目:
论著
出版日期:
2020-01-15

文章信息/Info

Title:
Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases
文章编号:
1006-1959（2020）02-0089-05
作者:
张小雨; 严 艳
（大连医科大学附属第二医院消化1科，辽宁 大连 116000）
Author(s):
ZHANG Xiao-yu; YAN Yan
(Department of Gastroenterology,Subject One,the Second Affiliated Hospital of Dalian Medical University,Dalian 116000,Liaoning,China)
关键词:
自身免疫性肝炎; 原发性胆汁性胆管炎; 肝外自身免疫性疾病; 肝纤维化; 肝硬化
Keywords:
Autoimmune hepatitis; Primary biliary cholangitis; Extrahepatic autoimmune disease;  Liver fibrosis; Cirrhosis
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2020.02.024
文献标志码:
A
摘要:
目的 比较自身免疫性肝炎（AIH）合并原发性胆汁性胆管炎（PBC）或部分肝外自身免疫性疾病（autoimmune disease）患者与单纯AIH患者临床特点及并发症，为改善AIH患者的诊治提供参考。方法 收集1999年8月~2019年8月我院收治的AIH患者149例，根据合并症分为无合并病的AIH组（68例）、AIH合并PBC组（AIH-PBC 组，41例）及AIH合并肝外自身免疫性疾病组（AIH-肝外组，40例），比较三组临床特点、并发症、肝纤维化/肝硬化进展情况。结果 ①AIH-PBC 组及AIH-肝外组年龄低于AIH组，差异有统计学意义（P＜0.05）；三组性别比较，差异无统计学意义（P＞0.05）。②三组共有的临床症状为瘙痒、黄疸、乏力、食欲不振及腹部不适，其中AIH-PBC组瘙痒症状患者多于AIH组、AIH-肝外组，差异有统计学意义（P＜0.05）；三组黄疸、乏力、食欲不振及腹部不适比较，差异无统计学意义（P＞0.05）。③AIH-PBC 组ALT低于AIH组及AIH-肝外组，ALP、GGT高于AIH组及AIH-肝外组，差异有统计学意义（P＜0.05）；AIH-肝外组的AST、DBIL高于AIH组及AIH-PBC 组，差异有统计学意义（P＜0.05）；AIH-肝外组IgG水平高于AIH组及AIH-PBC 组，差异有统计学意义（P＜0.05）。④三组ANA、ASMA、SLA、LKM-1阳性率比较，差异无统计学意义（P＞0.05）；AIH-PBC组AMA、AMA-M2 阳性率高于AIH组、AIH-肝外组，差异有统计学意义（P＜0.05）。⑤三组均以界面性肝炎和淋巴细胞浸润表现居多，其中AIH-PBC组胆管病变、胆汁淤积高于AIH组，差异有统计学意义（P＜0.05）。⑥三组并发症主要包括食管胃底静脉曲张/破裂出血、腹水、肝性脑病、肝癌、肝移植，组间比较，差异无统计学意义（P＞0.05）。⑦三组肝纤维化/肝硬化发生率比较，差异无统计学意义（P＞0.05）；但AIH-PBC组2~5年肝纤维化/肝硬化进展率高于AIH组及AIH-肝外组，差异有统计学意义（P＜0.05）。结论 合并PBC的AIH患者比单纯AIH患者诊断年龄早，肝脏炎症反应轻、胆管病变重；比AIH及合并肝外自身免疫性疾病更易出现瘙痒、胆汁淤积更重、胆管损伤更严重，且肝纤维化/肝硬化速度更快。AMA、AMA-M2可作为AIH合并PBC的鉴别指标。另外，AIH合并肝外自身免疫性疾病常存在肝功能损害，IgG对其具有提示意义。
Abstract:
Objective To compare the clinical characteristics and complications of patients with autoimmune hepatitis (AIH) with primary biliary cholangitis (PBC) or some extrahepatic autoimmune disease and patients with AIH alone, to provide a reference for improving the diagnosis and treatment of patients with AIH. Methods A total of 149 AIH patients admitted in our hospital from August 1999 to August 2019 were collected and divided into AIH group without complications (68 cases), AIH combined with PBC group (AIH-PBC group, 41 cases), and AIH according to comorbidities. The extrahepatic autoimmune disease group (AIH-extrahepatic group, 40 cases) was combined, and the clinical characteristics, complications, and liver fibrosis/cirrhosis progress were compared among the three groups.Results ①The age of AIH-PBC group and AIH-extrahepatic group was lower than AIH group, the difference was statistically significant (P<0.05); there was no statistically significant difference between the three groups (P>0.05). ②The clinical symptoms common to the three groups were pruritus, jaundice, fatigue, loss of appetite, and abdominal discomfort. Among the patients in the AIH-PBC group, there were more pruritus symptoms than in the AIH and AIH-extrahepatic groups,the difference was statistically significant (P<0.05);There was no significant difference in jaundice, fatigue, loss of appetite and abdominal discomfort among the three groups (P>0.05). ③AIH-PBC group had lower ALT than AIH group and AIH-extrahepatic group, ALP and GGT were higher than AIH group and AIH-extrahepatic group, the difference was statistically significant (P<0.05); AST and DBIL of AIH-extrahepatic group compared with AIH group and AIH-PBC group, the difference was statistically significant (P<0.05); AIH-extrahepatic group IgG levels were higher than AIH group and AIH-PBC group, the difference was statistically significant (P<0.05). ④ There was no significant difference in the positive rates of ANA, ASMA, SLA, and LKM-1 in the three groups (P>0.05). The positive rates of AMA and AMA-M2 in the AIH-PBC group were higher than those in the AIH and AIH-extrahepatic groups,the difference was statistically significant (P<0.05). ⑤The three groups were mostly manifested by interfacial hepatitis and lymphocyte infiltration. The bile duct lesions and cholestasis in the AIH-PBC group were higher than those in the AIH group,the differences were statistically significant (P<0.05). ⑥Complications in the three groups mainly included esophageal gastric fundus varices / rupture bleeding, ascites, hepatic encephalopathy, liver cancer, and liver transplantation,there was no significant difference between the groups (P>0.05).⑦There was no significant difference in the incidence of liver fibrosis / cirrhosis in the three groups (P>0.05); however, the progression rate of liver fibrosis / cirrhosis in the AIH-PBC group was higher than that of the AIH group and AIH-extrahepatic in 2 to 5 years,the difference was statistically significant (P<0.05).Conclusion Patients with AIH who have PBC are diagnosed earlier than patients with AIH alone. They have mild liver inflammation and severe bile duct lesions. They are more prone to pruritus, hepatic cholestasis, more severe bile duct injury, and hepatic fibrosis than AIH and patients with extrahepatic autoimmune diseases/cirrhosis is faster. AMA and AMA-M2 can be used as identification indicators for AIH combined with PBC. In addition, AIH with extrahepatic autoimmune diseases often has liver damage, and IgG has implications for it.

参考文献/References:

[1]Gerven NMFV,Verwer BJ,Witte BI,et al.Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands[J].Scand J Gastroenterol,2014(49):1245-1254. [2]Dalekos GN,Koskinas J,Papatheodoridis GV.Papatheodoridis. Hellenic Association for the Study of the Liver Clinical Practice Guidelines:Autoimmune hepatitis[J].Ann Gastroenterol 2019,32(1):1-23. [3]田辉.自身免疫性肝病相关性风湿病样及皮肤表现[J].临床肝胆病杂志,2018,34(9):2021-2026. [4]Manns MP,Czaja AJ,Gorham JD,et al.Diagnosis and management of autoimmune hepatitis[J].Hepatology,2010,51(6):2193-2213． [5]Chazouillères O,Wendum D,Serfaty L,et al.Primary biliary cirrhosis- autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J].Hepatology,1998,28(2):296. [6]Park Y,Cho Y,Cho EJ,et al.Retrospective analysis of autoimmune hepatitis -primary biliary cirrhosis overlap syndrome in Korea:characteristics,treatments,and outcomes[J].Clin Mol Hepatol,2015,21(2):150-157. [7]王星星,王盼盼,杨旭燕.系统性红斑狼疮合并器官特异性自身免疫性疾病的相关研究进展[J].浙江大学学报(医学版),2018,47(4):435-440. [8]朱林林,杨李桦,谢其冰.自身免疫性肝炎合并干燥综合征的临床病理特点分析[J].四川大学学报(医学版),2018,49(2):183-187. [9]熊玮珏,曹珊,张国艳.激素治疗自身免疫性肝炎并发淋巴细胞性间质性肺炎1例报告[J].临床肝胆病杂志,2019(7):1596-1598. [10]范晓飞,林睿,罗莉丽,等.自身免疫性肝炎合并肝外自身免疫疾病患者的临床特点观察[J].山东医药,2014,54(40):75-77. [11]Narsing Rao L,Jacob JJ,Paul TV,et al.Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulinresistance in adoloscentsand young adults with polycystic ovary syndrome[J].J Pediatr Adolesc Gynecol,2009,22(2):91-95. [12]Biró E,Szekanecz Z,Czirják L,et al.Association of systemic and thyroid autoimmune diseases[J].ClinR heumatol,2006,25(2):240-245. [13]王婷婷,鲁昌立,凡小丽,等.自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征的临床及病理学特征分析[J].临床肝胆病杂志,2017,33(11):2179-2185. [14]尧颖,高建鹏,王辉.自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征患者肝组织病理学特征[J].肝脏,2018,23(9):769-771. [15]To U,Silveira M.Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis[J].Clinics in liver disease,2018,22(3):603-611. [16]Sebode M,Hartl J,Vergani D,et al.Autoimmune hepatitis:From current knowledge and clinical practice to future research agenda[J].Liver Int,2018,38(1):15-22.

相似文献/References:

[1]和重祥.原发性胆汁性胆管炎抗体及肝外疾病研究[J].医学信息,2019,32(12):50.[doi:10.3969/j.issn.1006-1959.2019.12.016]
　HE Chong-xiang.Primary Biliary Cholangitis Antibody and Extrahepatic Disease Research[J].Medical Information,2019,32(02):50.[doi:10.3969/j.issn.1006-1959.2019.12.016]
[2]张 赓.自身抗体在自身免疫性肝炎和乙型病毒性肝炎中的特征分析[J].医学信息,2020,33(05):173.[doi:10.3969/j.issn.1006-1959.2020.05.059]
　ZHANG Geng.Analysis of the Characteristics of Autoantibodies in Autoimmune Hepatitis and Viral Hepatitis B[J].Medical Information,2020,33(02):173.[doi:10.3969/j.issn.1006-1959.2020.05.059]
[3]陈 薇,洪汝涛.FIB-4、APRI指数对自身免疫性肝炎肝脏炎症坏死的预测价值[J].医学信息,2020,33(10):96.[doi:10.3969/j.issn.1006-1959.2020.10.025]
　CHEN Wei,HONG Ru-tao.The Predictive Value of FIB-4 and APRI Index for Liver Inflammation and Necrosis of Autoimmune Hepatitis[J].Medical Information,2020,33(02):96.[doi:10.3969/j.issn.1006-1959.2020.10.025]

更新日期/Last Update: 2020-01-15